Dr. Clemens Fischer – Why this entrepreneur was sure he should invest hundreds of millions in a drug
Dr. Clemens Fischer – Entrepreneur has received approval for a new pain medication developed by his company Vertanical. He hopes it will end opioid treatments. He wishes politicians would show more courage.
Now that Vertanical’s Exilby has been approved in Germany to treat chronic pain, Clemens Fischer, the pharma billionaire behind it, has set his sights on the U.S. market. ‘There is no plan B for me.’
The marketing authorization in Germany has been granted after two pivotal randomized, controlled Phase 3 trials involving more than 1,200 patients demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence1. In a direct Phase 3 head-to-head comparator study, Exilby® also showed superior pain reduction and better gastrointestinal tolerability than opioids, reinforcing its potential as a differentiated non-opioid alternative in chronic pain care2.